Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

This study compares two treatments in people with liver cancer (HCC) that has stopped responding to a common procedure called TACE (a procedure that delivers chemotherapy directly into the tumor's blood supply): one group gets lenvatinib (a targeted drug) plus radiation delivered through tiny beads injected into the liver (SIRT), while the other gets lenvatinib alone. **You may be eligible if...** - You have been diagnosed with liver cancer (HCC) - Your cancer has stopped responding to TACE treatment - You have at least one measurable tumor in the liver - Your liver function is preserved (Child-Pugh A or B) - Your general health is good (ECOG 0–1) - Your tumor takes up less than 70% of the liver - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread outside the liver - You have serious liver dysfunction - You have had prior treatment with lenvatinib or similar targeted drugs Talk to your doctor to see if this trial is right for you.